ReviewField cancerization in mammary carcinogenesis — Implications for prevention and treatment of breast cancer
Section snippets
Cancer is a multistep molecular and cellular process
The development of a clinical cancer occurs over a long period of time and requires multiple molecular alterations and evolution of cellular populations with increasingly aggressive phenotypic characteristics. While the time required for completion of the process of carcinogenesis is not well established for any form of human cancer, estimates suggest that this process unfolds over decades. It follows that most cancers are diseases of old (or older) age, although there are exceptions (pediatric
Molecular and cellular heterogeneity of cancer
A lasting paradigm of cancer biology is that cancer is a disease of clonal growth. Hence, the multicellular disease that is cancer originates in a single cell. This concept has been variously described in simplistic terms. Fig. 1 depicts the clonal evolution of cancer — beginning with a normal epithelial cell and ending with a clinical metastatic cancer. This conceptual depiction emphasizes the multiple steps that occur during carcinogenesis, with multiple molecular alterations and multiple
Field cancerization
Field cancerization was first proposed to account for the multiple cancers that develop in cigarette smokers within the carcinogen-exposed field that comprises the aerodigestive tract (Slaughter et al., 1953). Since the first description of field cancerization, this concept has been applied to cancers in many different tissues (Chai and Brown, 2009). The idea of field cancerization fits very well for carcinogen-exposed tissue fields (like cigarette smoke-exposed respiratory epithelium or
Natural history and molecular classification of breast cancer
Breast cancer is a heterogeneous disease characterized by variant pathological features, disparate response to therapeutics, and substantial differences in long-term patient survival. DNA microarray-based transcription profiling of invasive breast cancer identified distinct and reproducible molecular subtypes that are associated with different clinical outcomes (Perou et al., 2000, Sorlie et al., 2001, Sorlie et al., 2003, Sotiriou et al., 2002, Sotiriou et al., 2003, van de Vijver et al., 2002
Molecular alterations in breast cancer
The development of breast cancer occurs in response to an accumulation of genetic and epigenetic abnormalities that drive uncontrolled growth of breast epithelial cells. The primary manifestation of the genetic and epigenetic abnormalities occurring in breast cancer are reflected in the cellular behaviors observed in cancer cells (autonomy of growth control, resistance to growth suppression and apoptosis, ability to invade local and metastasize to distant sites) and the underlying gene
Epigenetic alterations in breast cancer
Neoplastic transformation is associated with alterations in DNA methylation, including both global hypomethylation and gene-specific hypermethylation (Baylin, 2001, Baylin et al., 1998, Herman and Baylin, 2003). Hypomethylation of cancer cell genomes is associated with loss of methylation in CpG-depleted regions where most CpG dinucleotides would be expected to be methylated (Feinberg and Vogelstein, 1983a, Feinberg and Vogelstein, 1987, Goelz et al., 1985). The loss of methylation in these
Field cancerization in breast cancer
Numerous lines of evidence suggest that breast cancers may develop through field cancerization, including significant observations made in patients with early (pre-invasive) breast neoplasms (DCIS). Molecular evidence for field cancerization in the breast includes the observation of both genetic and epigenetic alterations in otherwise normal appearing breast epithelium. Genomic instability in the form of allelic imbalances have been characterized in histologically normal breast tissue adjacent
Field cancerization in early breast cancer — implications for treatment
DCIS is typically treated with surgery (either lumpectomy or mastectomy) and local radiation treatment (for patients undergoing breast conserving surgery). Patients undergoing local excision and radiation therapy have a higher risk for local recurrence (12% of these patients develop recurrent disease) than patients who choose mastectomy (1% of these patients develop recurrent disease) (Allegra et al., 2010). Currently, > 500,000 women are alive that have a prior diagnosis of DCIS (Allegra et
Perspective
Given the prevalence of DCIS (pure DCIS or DCIS associated with invasive breast cancer), expansion and improvement of our understanding of the molecular pathogenesis of this disease is essential to the development of new strategies for effective prevention of breast cancer and improved treatment of patients with pre-invasive or invasive breast neoplasms. With development of a greater understanding of the required molecular alterations that drive breast cancer, biomarkers for premalignant stages
Conflict of Interest statement
The authors declare no conflicts of interest.
References (75)
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer
Modern Pathology
(2006)Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile
Modern Pathology
(2006)- et al.
A genetic model for colorectal tumorigenesis
Cell
(1990) - et al.
Hypomethylation of ras oncogenes in primary human cancers
Biochemical and Biophysical Research Communications
(1983) - et al.
The hallmarks of cancer
Cell
(2000) - et al.
Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells
Gene
(1998) Identification of a basal-like subtype of breast ductal carcinoma in situ
Human Pathology
(2007)Molecular discrimination of multiple primary versus metastatic squamous cell cancers of the head/neck and lung
Experimental and Molecular Pathology
(2009)DNA methylation-dependent silencing of CST6 in human breast cancer cell lines
Laboratory Investigation
(2006)Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions
Experimental and Molecular Pathology
(2007)
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities
European Journal of Cancer
National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ september 22–24, 2009
Journal of the National Cancer Institute
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution
Clinical Cancer Research
Hypermethylation in histologically distinct classes of breast cancer
Clinical Cancer Research
DNA methylation and epigenetic mechanisms of carcinogenesis
Developments in Biologicals
Alterations in DNA methylation: a fundamental aspect of neoplasia
Advances in Cancer Research
Genetic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis
Cold Spring Harbor Symposia on Quantitative Biology
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
JAMA: The Journal of the American Medical Association
APC and colon cancer: two hits for one
Nature Medicine
Field effect in cancer—an update
Annals of Clinical and Laboratory Science
Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers
Cancer Research
Epigenetic silencing of maspin gene expression in human breast cancers
International Journal of Cancer
Chromosomal instability and tumors promoted by DNA hypomethylation
Science
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma
International Journal of Cancer
Hypomethylation distinguishes genes of some human cancers from their normal counterparts
Nature
Alterations in DNA methylation in human colon neoplasia
Seminars in Surgical Oncology
Induction of tumors in mice by genomic hypomethylation
Science
Hypomethylation of DNA from benign and malignant human colon neoplasms
Science
Classification of ductal carcinoma in situ by gene expression profiling
Breast Cancer Research
Chemical and physical carcinogenesis: Advances and perspectives for the 1990s
Cancer Research
Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors
International Journal of Cancer
Mammary field cancerization: molecular evidence and clinical importance
Breast Cancer Research Treat.
Tumor heterogeneity
Cancer Research
The cellular basis of tumor progression
International Review of Cytology
Mammary tumor heterogeneity
Symposium on Fundamental Cancer Research
Gene silencing in cancer in association with promoter hypermethylation
The New England Journal of Medicine
Methylation profiling of CpG islands in human breast cancer cells
Human Molecular Genetics
Cited by (40)
An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device
2020, Computer Methods and Programs in BiomedicineCitation Excerpt :They also describe how, conversely, oncogenic processes can continue to weaken the circadian rhythms and enable cancer proliferation. Moreover, field cancerization studies identified alterations in normal tissues surrounding areas of overt cancer [24,40–42]. Based on these findings, it is believed that even if a cancerous lesion is situated deep inside the breast and is relatively small (≤0.5 cm in diameter) and not palpable, the reduced PER2 protein activity and ensuing altered circadian rhythm will be observed throughout the tissue.
Field cancerization in the understanding of parenchymal analysis of mammograms for breast cancer risk assessment
2020, Medical HypothesesCitation Excerpt :In the framework of FC, the breast cancer can be described as a multi-step molecular and cellular process involving genetic mutations and epimutations consistent with the non-locality of the FC [24]. For instance, in hereditary forms of breast cancer, e.g., BRCA1/2 carriers, the altered field can reflect the entire breast tissue, which is composed of cells with a predisposing molecular lesion [24]. Molecular evidence for FC in the breast includes the observation of both genetic and epigenetic alterations in otherwise normal-appearing breast tissue [25–27].
Cancer-associated fibroblasts in tumor microenvironment – Accomplices in tumor malignancy
2019, Cellular ImmunologyApplication of Single-Cell Omics in Breast Cancer
2019, Single-Cell OmicsApplication of single-cell omics in breast cancer
2019, Single-Cell Omics: Volume 2: Application in Biomedicine and Agriculture